Our working hypothesis is that LTD4 or TNF-α induces airway hyperresponsiveness in human distal bronchi (0.5–0.8 mm diameter) and that RvD2 treatment inhibits the main inflammatory biomarkers in distal airways which in turn, would result in lower bronchial reactivity. Here, TNF is linked to airway hyperresponsiveness.